HPTO yields 1104.97% · ABBV yields 3.09%● Live data
📍 HPTO pulled ahead of the other in Year 1
Combined, HPTO + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of HPTO + ABBV for your $10,000?
hopTo Inc., together with its subsidiaries, develops and sells application publishing software in the United States, Brazil, Japan, Germany, the Netherlands, and internationally. The company's application publishing software includes application virtualization and cloud computing software for a range of computer operating systems, including Windows, UNIX, and various Linux-based variants. It provides its application publishing software solutions under the GO-Global brand name. The company offers GO-Global, an application access solution that provides cross-platform remote access and Web-enabled access to existing software applications, as well as the deployment of secure and private cloud environments for use and/or resale by independent software vendors, corporate enterprises, governmental and educational institutions, and others. Its GO-Global software products comprise GO-Global for Windows that allows access to Windows-based applications from remote locations and Internet connections; GO-Global for UNIX, which allows access to UNIX and Linux-based applications from remote locations, and Internet and connections; and GO-Global Client that allows remote application access from various local, remote, and mobile platforms, including Windows, Linux, UNIX, Apple OS X and iOS, and Google Android. The company sells its products through resellers, such as original equipment manufacturers, system integrators, value-added resellers, and distributors. It serves small to medium-sized companies, departments within large corporations, governmental and educational institutions, and independent software vendors. The company was formerly known as GraphOn Corporation and changed its name to hopTo Inc. in September 2013. hopTo Inc. was incorporated in 1996 and is headquartered in Concord, New Hampshire.
Full HPTO Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.